Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 11.

Steinman, L; Bar-Or, A; Behne, J M; Benitez-Ribas, D; Chin, P S; Clare-Salzler, M; Healey, D; Kim, J I; Kranz, D M; Lutterotti, A; Martin, R; Schippling, S; Villoslada, P; Wei, C H; Weiner, H L; Zamvil, S S; Yeaman, M R; Smith, T J (2016). Restoring immune tolerance in neuromyelitis optica: Part I. Neurology: Neuroimmunology and Neuroinflammation, 3(5):e276.

Bar-Or, A; Steinman, L; Behne, J M; Benitez-Ribas, D; Chin, P S; Clare-Salzler, M; Healey, D; Kim, J I; Kranz, D M; Lutterotti, A; Martin, R; Schippling, S; Villoslada, P; Wei, C H; Weiner, H L; Zamvil, S S; Smith, T J; Yeaman, M R (2016). Restoring immune tolerance in neuromyelitis optica: Part II. Neurology: Neuroimmunology and Neuroinflammation, 3(5):e277.

Maurer, M A; Tuller, F; Gredler, V; Berger, T; Lutterotti, A; Lünemann, J D; Reindl, M (2016). Rituximab induces clonal expansion of IgG memory B-cells in patients with inflammatory central nervous system demyelination. Journal of Neuroimmunology, 290:49-53.

Bsteh, G; Ehling, R; Lutterotti, A; Hegen, H; Di Pauli, F; Auer, M; Deisenhammer, F; Reindl, M; Berger, T (2016). Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study. PLoS ONE, 11(7):e0158978.

Ramberger, M; Bsteh, G; Schanda, K; Höftberger, R; Rostásy, K; Baumann, M; Aboulenein-Djamshidian, F; Lutterotti, A; Deisenhammer, F; Berger, T; Reindl, M (2015). NMDA receptor antibodies: A rare association in inflammatory demyelinating diseases. Neurology: Neuroimmunology and Neuroinflammation, 2(5):e141.

Hametner, E; Unterberger, I; Lutterotti, A; Beer, R; Prieschl, M; Grams, A E; Donnemiller, E; Stockhammer, G (2015). Non-convulsive status epilepticus with negative phenomena--a SMART syndrome variant. Seizure, 25:49-51.

Ehling, R; Lutterotti, A; Brenneis, C; Zee, D S; Beh, S C; Kheradmand, A (2014). Damping of monocular pendular nystagmus with vibration in a patient with multiple sclerosis. Neurology, 83(20):1879.

Lutterotti, A; Martin, R (2014). Antigen-specific tolerization approaches in multiple sclerosis. Expert Opinion on Investigational Drugs, 23(1):9-20.

Lutterotti, A; Yousef, S; Sputtek, A; Stürner, K H; Stellmann, J P; Breiden, P; Reinhardt, S; Schulze, C; Bester, M; Heesen, Ch; Schippling, S; Miller, S D; Sospedra, M; Martin, R (2013). Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Science Translational Medicine, 5(188):188ra75.

Lutterotti, A; Jelcic, I; Schulze, C; Schippling, S; Breiden, P; Mazzanti, B; Reinhardt, S; DiGioia, M; Repice, A; Massacesi, L; Sputtek, A; Salinas-Riester, G; Kroeger, N; Sospedra, M; Saccardi, R; Zander, A; Martin, R (2012). No proinflammatory signature in CD34+ hematopoietic progenitor cells in multiple sclerosis patients. Multiple Sclerosis Journal, 18(8):1188-1192.

Lünemann, J D; Jelcic, I; Roberts, S; Lutterotti, A; Tackenberg, B; Martin, R; Münz, C (2008). EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. Journal of Experimental Medicine, 205(8):1763-1773.

This list was generated on Tue Dec 12 18:12:12 2017 CET.